Genetic Technologies (AU:GTG) has released an update.
Genetic Technologies Limited reports a striking finding from their geneType Risk Assessment Tests: 79.5% of participants are at elevated risk for serious diseases. Their innovative Multi-Risk Test, which is non-invasive and covers a range of critical diseases, is changing the healthcare approach towards early detection and personalized preventive care. These results underscore the test’s potential in improving health outcomes by enabling proactive management and informed decision-making.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
